Business development stage

The drug is at the stage of clinical trials of the 1st phase. We have resources for their implementation.

For entry into the market, it is necessary to conduct:

Clinical trials of the 2nd phase (randomized controlled trial with assessment of the drug safety and efficacy compared to the reference drug);

Clinical trials of the 3rd phase (randomized controlled multicentre trial involving a large population of patients);

Marketing stage - entry of the drug into the market on indications of prevention of deep vein thrombosis and pulmonary embolism after knee or hip replacement surgeries;

Post-registration stage - continuation of clinical trials (the 4th phase) with the aim of expanding indications of use (prevention of thrombosis in atrial fibrillation).